Jammu and Jammu are awaiting approval of new plant to ship high volumes of vaccines: execution

Stoffels said he expected the catalytic plant to be approved within the next few days and that the company would be able to deliver on its promise to supply 20 million doses of the vaccine by the end of March.

Jammu and Kashmir is also working to expand its manufacturing capacity globally and is in talks with potential new partners, Stoffels said, adding that he hopes to be able to announce more manufacturing deals soon is.

“Those discussions are going on,” he said.

Those plans include an expansion in India, where the company is working this year to bring a plant with a higher capacity that will “serve a much larger part of the world”, Stoffels said.

The managing director of the Indian pharmaceutical company Biological E Ltd told Reuters last month that his company was seeking to contract about 600 million doses of the COVID-19 vaccine annually in Jammu and Kashmir.